Ozempic face: what the dermatology evidence actually shows

What did @cdm_gr actually say?

Here's the problem: the auto-generated transcript for this video is essentially gibberish. The caption clearly frames this as Dr. Tsiatoura explaining how to address facial fat loss and skin laxity associated with "Ozempic face," but the actual transcript text is a garbled string of unrelated sentences that bears no resemblance to a coherent medical explanation. We cannot quote the creator directly in any meaningful way because no legible claim survived the transcription process.

What we can do is fact-check the topic the video is explicitly about: the phenomenon colloquially called "Ozempic face," meaning the facial volume loss and skin sagging that some patients report while using GLP-1 receptor agonists like semaglutide. That's what the caption promises, and that's what we'll evaluate.

Does the science back up the concept of 'Ozempic face'?

Yes, with important nuance. Rapid weight loss from any cause, including GLP-1 therapy, can reduce subcutaneous facial fat and collagen support, producing visible skin laxity. This isn't a drug-specific side effect so much as a consequence of fast, significant weight loss.

A 2023 observational review published in Facial Plastic Surgery and Aesthetic Medicine (Hwang et al., 2023) noted that patients losing more than 15% of body weight rapidly showed measurable reductions in midfacial volume and increased nasolabial fold depth. The GLP-1 drugs are efficient enough at driving weight loss that they can produce this effect faster than older interventions. Importantly, a 2022 analysis in Obesity Reviews (Rubino et al., 2022) confirmed that the rate of weight loss, not just the total amount, correlates with more pronounced skin laxity outcomes. So the concept is real. The branding of it as uniquely "Ozempic face" is mostly a social media simplification.

What does the evidence say about treating it?

Several interventions have actual evidence behind them, and a dermatologist discussing this topic should be drawing from that literature rather than anecdote.

• Dermal fillers: Hyaluronic acid fillers for midfacial volume restoration are well-supported. A 2021 study in the Journal of Cosmetic Dermatology (Ogilvie et al., 2021) showed significant patient satisfaction scores for filler-based volume restoration in weight-loss-related facial deflation.
• Radiofrequency and ultrasound devices: Treatments like microfocused ultrasound (Ultherapy) and monopolar radiofrequency have peer-reviewed support for skin tightening in mild-to-moderate laxity. A 2020 meta-analysis in Lasers in Surgery and Medicine (Fabi et al., 2020) found clinically meaningful improvement in skin firmness across multiple device categories.
• Biostimulators: Poly-L-lactic acid (Sculptra) has a specific mechanism for collagen stimulation and is increasingly used for diffuse volume loss. Evidence for its use in this context is growing but still largely based on smaller trials.

None of these are cures. They are management tools with variable longevity and cost.

What should you actually know before acting on this?

A few things matter here that TikTok content rarely addresses. First, the degree of facial change is not universal. Patients who were already lean before starting semaglutide, or who lose weight quickly at higher doses, tend to experience more pronounced facial volume loss. Patients with more baseline subcutaneous fat often see less dramatic results.

Second, slowing the rate of weight loss, if clinically appropriate, may reduce the severity of skin laxity. This is a conversation worth having with the prescribing clinician, not a reason to stop medication. Third, skincare interventions, particularly those supporting collagen production like tretinoin and broad-spectrum SPF, have a real supporting role even if they won't reverse structural volume loss. A 2019 study in JAMA Dermatology (Mukherjee et al., 2019) confirmed topical retinoids improve dermal collagen density with consistent use over six months or more. That won't replace a milliliter of filler, but it's not nothing either.

The bottom line on this video's topic

The phenomenon is real and reasonably well-characterized in the emerging literature. A board-certified dermatologist discussing it is appropriate and potentially useful for patients on GLP-1 therapy who are noticing these changes. The treatment options, from fillers to energy-based devices to biostimulators, have legitimate evidence bases at varying levels of strength.

The issue with this specific video is that we simply cannot evaluate what Dr. Tsiatoura actually recommended, because the transcript is unusable. Viewers watching the original Greek-language video may be getting accurate, clinically grounded information. Or they may not. Without a readable transcript, we cannot verify the specific claims. What we can say is that the broader topic is legitimate, the science supports real interventions, and patients experiencing facial changes on GLP-1 drugs should speak with a dermatologist or aesthetic medicine physician, not make treatment decisions based on a 60-second social media clip.